But a crowded obesity market demands product differentiation, fewer side effects, and benefits beyond weight loss to reap financial gains.
The UK-based pharma giant lists its stock on NYSE even as it continues overseas manufacturing and innovation spending.
Pharma and health brands return to the Super Bowl, ditching drug pitches for brand storytelling campaigns.
D2C pharma brands must ensure their cash-pay programs and telehealth ties are transparent and compliant with anti-kickback laws.
Better-staffed pharmacies could become Walmart’s edge, even as more consumers move online.
Studies link higher AFib detection to watch wearers, strengthening wearables’ medical case.
Novo’s oral drug is wildly outperforming weekly sales needed to hit forecasts, signaling strong early demand for GLP-1 pills.
Rising demand clashes with high costs, no insurance coverage, and doctors’ reluctance to validate outside results.
The revenue hit to pharma should be modest, but drug-pricing headwinds will force manufacturers to trade margin for volume and push harder on prices abroad.
More than one-third of Gen Z and millennials turn to AI for stigma-free support.
Benefits emerge with adherence, increasing pressure on employers to keep coverage.
Health and wellness is the only category where plans to increase spending outweigh plans to cut back in 2026, according to December 2025 data from CivicScience. That’s why retailers are stepping up their investments in wellness-driven products, services, and in-store experiences, trying to capitalize on consumers’ resolutions well into the new year.
Clinicians and staff adopt “shadow AI” tools to move faster, exposing gaps in hospital AI strategy.
Wisp acquires TBD Health to scale nationwide, adding clinics and diagnostics to meet rising demand for virtual care among women.
The healthcare giant’s forecasted decline in revenues signals an industry-wide pivot from expansion to cost discipline.
Roche’s obesity drug results show up to 22.5% weight loss, hinting at future competition for Novo and Lilly.
Major regulatory upheaval affecting pharma’s core business is unlikely to materialize this year.
Heavy consumer AI health use raises pressure on OpenAI and peers to tighten safeguards fast.
Lilly’s tirzepatide is projected to top 2026 sales as pills and uses beyond diabetes and weight loss expand demand.
51% US consumers now notice healthcare and pharma advertising on CTV, putting it ahead of search and social.